General Information of Drug (ID: DMNOU59)

Drug Name
GSK'963 Drug Info
Indication
Disease Entry ICD 11 Status REF
Myeloid leukaemia 2B33.1 Investigative [1]
Cross-matching ID
PubChem CID
122703613
TTD Drug ID
DMNOU59

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GSK2982772 DM7HNFV Plaque psoriasis EA90.0 Phase 2 [2]
DNL758 DM89D6C Cutaneous lupus erythematosus EB5Z Phase 2 [3]
Eclitasertib DM2O8VW Ulcerative colitis DD71 Phase 2 [4]
SAR443820 DMNCP7B Amyotrophic lateral sclerosis 8B60.0 Phase 2 [5]
GSK3145095 DM059OH Pancreatic cancer 2C10 Phase 1/2 [6]
R552 DM5XCRQ Nervous system paraneoplastic or autoimmune disorders 8E4A.1 Phase 1 [3]
DNL747 DMNSC0O Alzheimer disease 8A20 Phase 1 [3]
DNL104 DMOSCQ9 Alzheimer disease 8A20 Phase 1 [7]
Tricyclic compound 10 DMV1RQX N. A. N. A. Patented [8]
Tricyclic compound 8 DMZI8GK N. A. N. A. Patented [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Receptor-interacting protein 1 (RIPK1) TTAIQSN RIPK1_HUMAN Inhibitor [1]

References

1 Characterization of GSK'963: a structurally distinct, potent and selective inhibitor of RIP1 kinase. Cell Death Discov. 2015 Jul 27;1:15009.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov. 2020 Aug;19(8):553-571.
4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
5 ClinicalTrials.gov (NCT05237284) A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR443820 in Adult Participants With Amyotrophic Lateral Sclerosis, Followed by an Open-label Extension. U.S.National Institutes of Health.
6 Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer. ACS Med Chem Lett. 2019 May 9;10(6):857-862.
7 DNL104, a Centrally Penetrant RIPK1 Inhibitor, Inhibits RIP1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers. Clin Pharmacol Ther. 2020 Feb;107(2):406-414.
8 Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patents.Expert Opin Ther Pat. 2016 Nov;26(11):1239-1256.